Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib

Fig. 7

The effects of added axitinib to supplement a bosutinib and asciminib combination. Drug doses are normalised such that bosutinib–asciminib achieves 90% growth reduction together and axitinib achieves 5% growth reduction. Bosutinib–asciminib (left) and axitinib–asciminib (right) are administered at t=0. Axitinib (left) and bosutinib (right) administration is indicated by the dotted vertical lines. All timings were freely optimised; simultaneous administration is optimal when indicated

Back to article page